Efficacy and safety of Yinchenwuling powder for hyperlipidemia: a systematic review and Meta-analysis  by Haiqiang, Yao et al.
JTCM |www. journaltcm. com April 15, 2016 |Volume 36 | Issue 21 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2016 April 15; 36(2): 135-143
info@journaltcm.com ISSN 0255-2922
© 2016 JTCM. All rights reserved.
SYSTEMATIC REVIEW
Efficacy and safety of Yinchenwuling powder for hyperlipidemia: a
systematic review andMeta-analysis
Yao Haiqiang, Zhang Zengliang, Wang Ji, Zuo Jiacheng, Chen Yu, Zhu Libing, Li Xiaoke, Yang Zheng, Wang
Zisong, Sun Ranran, Xu Xuanxuan, Li Changming,WuYanling, Li Lingru,Wang Qi
aa
Yao Haiqiang, Wang Ji, Libing Zhu, Li Xiaoke, Yang
Zheng, Wang Zisong, Sun Ranran, Xu Xuanxuan, Li
Changming, Wu Yanling, Li Lingru, Wang Qi, Basic Medi-
cal College, Beijing University of Chinese Medicine, Beijing
100029, China
Zhang Zengliang, Traditional Chinese Medicine College, In-
ner Mongolia Medical University, Hohhot 010110, China
Chen Yu, Department of Nutrition, Chinese-Japan Friend-
ship Hospital, Beijing 100029, China
Supported by the Chinese National Natural Science Foun-
dation Key Project (Identification of the Molecular Signature
Contributing to the Susceptibility of Phlegmatic Hygrosis
Constitution to Metabolic Syndrome, No. 81030064)
Correspondence to: Li Lingru and Wang Qi, Basic Medical
College, Beijing University of Chinese Medicine, Beijing
100029, China. llilingru912@163.com; wangqi710@126.com
Telephone: +86-10-64286766
Accepted: December 3, 2015
Abstract
OBJECTIVE: To assess the clinical effectiveness and
adverse effects of Yinchenwuling powder (YCWLP)
in the treatment of hyperlipidemia using Meta-anal-
ysis.
METHODS: Seven electronic databases were
searched for randomized controlled trials designed
to evaluate the clinical effectiveness of YCWLP for
hyperlipidemia published in any language prior to
February 2015. Two reviewers independently identi-
fied articles, extracted data, assessed quality, and
cross-checked the results. Revman 5.3 was used to
analyze the data.
RESULTS: Only five randomized controlled trials
with poor methodology were included in the analy-
sis. The five trials compared YCWLP with conven-
tional lipid-lowering drugs. Meta-analysis indicated
that YCWLP was more effective at the levels of total
cholesterol and triglycerides, while increasing the
level of high-density lipoprotein cholesterol with-
out serious adverse effects. However, it was not
more effective than lipid-lowering drugs in reduc-
ing low-density lipoprotein cholesterol and improv-
ing hemorheology.
CONCLUSION: YCWLP appeared to improve lipid
levels. However, given the high risk of bias among
the trials, we could not conclude that YCWLP was
beneficial to patients with hyperlipidemia. More rig-
orous trials are required to provide stronger evi-
dence for the conclusion.
© 2016 JTCM. All rights reserved.
Key words: Hyperlipidemias; Review; Meta-analy-
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INTRODUCTION
Hyperlipidemia refers to elevated lipid levels in blood.1
The condition is also called hyperlipemia, lipemia, or
lipidemia, and includes elevated total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C), and total
triglyceride (TG) levels in the blood.2 Hyperlipidemia
is a major risk factor for cardiovascular and cerebrovas-
cular disease.3,4 Hyperlipidemia can induce atherosclero-
sis, which can lead coronary heart disease, stroke, and
myocardial infarction.5,6 Approximately 33.5% of the
adult population in the United States has elevated se-
rum cholesterol levels, and millions of people world-
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wide are affected.7 The incidence of hyperlipidemia is
gradually increasing, and may worsen with an aging
population. Therefore, the prevention and manage-
ment of hyperlipidemia is important.8 Hypolipidemic
agents commonly used in clinic include polyene unsat-
urated fatty acids, statins, fibrates, nicotinic acids, ezeti-
mibe, probucol, and other compound preparations.9
However, almost all of the main lipid-lowering drugs
cause side effects. For instance, statins cause myopathy
in approximately 10% of patients receiving treat-
ment.10 An estimated 20% of patients are statin-resis-
tant or intolerant;11 novel treatments are therefore re-
quired.
In several Asian countries, such as China, Korea, and
Japan, herbs have been widely used in the treatment of
hyperlipidemia. The etiology and pathogenesis of hy-
perlipidemia in Traditional Chinese Medicine (TCM)
is pathogenic dampness, a TCM symptom pattern
identified in terms of TCM's theory. Because of body
fluid Metabolic disturbances, excessive phlegm-damp-
ness stays within the body, affecting blood circulation
and causing hyperlipidemia.12,13 Based on the symptom
pattern identified, and experience from the manage-
ment of hyperlipidemia with TCM, a specific formula,
Yinchenwuling powder, was developed. YCWLP is
composed of: Yinchen (Herba Artemisiae Frigidae),
Guizhi (Ramulus Cinnamomi), Fuling (Poria), Baizhu
(Rhizoma Atractylodis Macrocephalae), Zexie (Rhizoma
Alismatis), and Zhuling (Polyporus). YCWLP is widely
used alone or combined with lipid-lowering drugs to
treat hyperlipidemia in China. Recent studies have
shown that YCWLP could obviously decrease the levels
of TC, TG, and LDL, increase high-density lipopro-
tein cholesterol (HDL), reduce blood viscosity, packed
cell volume, and platelet adhesion rate, maintain aorta
structure, and lower bcl-2 mRNA expression.14,15 Fur-
thermore, several clinical studies have reported effec-
tiveness of YCWLP. These studies range from case re-
ports and case series to controlled observational studies
and randomized clinical trials. However, critically ap-
praised evidence is not yet available, including system-
atic reviews or Meta-analyses. Therefore, we aimed to
evaluate the beneficial and harmful effects of YCWLP
for hyperlipidemia in randomized controlled trials.
METHODS
The protocol of this study was registered in the PROS-
PERO International prospective register of systematic
reviews (http://www.crd.york.ac.uk/PROSPERO/dis-
play_record.asp?ID=CRD42015019428).
Inclusion criteria
Types of study. All randomized controlled clinical trials
(RCTs) that assessed the effect of YCWLP for hyperlip-
idemia were included with no language restrictions. All
modified YCWLP combinations were also included.
No restrictions on the population characteristics, lan-
guage, or publication type were imposed.
Types of participant. Patients with hyperlipidemia who
were diagnosed with the criteria of "Screening and
management of lipids"6 and any other studies deemed
reasonable were included regardless of age, sex, or race
of the study participants.
Outcome measures. The primary outcome measures
were: TC, TG, LDL, HDL, and adverse events. The
second outcome indexes were effective rate and hemo-
dynamic indexes, including high shear rate blood vis-
cosity, low shear rate blood viscosity, and plasma viscos-
ity. The curative effect valuation standards were mainly
determined according to the "Chinese Adult Dyslipid-
emia Prevention Guide."17 "Effective rate" was defined
as TC decreasing by > 10%, TG decreasing by > 20%,
or restoration of one of the lipid indexes to normal af-
ter intervention. "Invalid" was defined as TC decreas-
ing by < 10%, TG decreasing by < 20%, or restoration
of none of the lipid indexes to normal after interven-
tion. "Worsened" was defined as TC or TG increasing
by > 10%, or other lipid indexes exceeding the normal
levels after intervention.
Search strategy
Literature searches were conducted in the three English
electronic databases: Cochrane Central Register of
Controlled Trials (CENTRAL) in the Cochrane Li-
brary, PubMed, EMBASE, and four Chinese databases:
Chinese Biomedical Literature Database (CBM), Chi-
nese National Knowledge Infrastructure (CNKI), Chi-
nese Scientific Journal Database (VIP), and the Wang-
fang Database for publications dating up to February
2015. First, we checked the subject headings through
Mesh database in MEDLINE and we found the sub-
ject word for hyperlipidemia as "Hyperlipidemias" and
free texts as Hyperlipemia, Hyperlipemias, Hyperlipid-
emia, Lipidemia, Lipidemias, Lipemia, and Lipemias.
There was no subject word for Yinchenwuling powder,
so we just used the free text as "yinchen wuling" and
"yin chen wu ling." Finally, we formulated the litera-
ture search formula for PubMed as follows:
#1: (Hyperlipidemias[MeSH Terms]) OR Hyperlipe-
mia[Title/Abstract]) OR Hyperlipemias[Title/Ab-
stract]) OR Hyperlipidemia[Title/Abstract]) OR Lipid-
emia[Title/Abstract]) OR Lipidemias[Title/Abstract])
OR Lipemia[Title/Abstract]) OR Lipemias[Title/Ab-
stract]
#2: ("yinchen wuling" [Title/Abstract]) OR "yin chen
wu ling" [Title/Abstract]
#3: Random[Title/Abstract]
#4: #1 and #2 and #3
When searching in Chinese databases, we first checked
CBM and VIP to retrieve synonyms, and then we for-
mulated the search formula as: ("Gao Zhi Xue Zheng"
or "Gao Xue Zhi Zheng" or "Gao Dan Bai Xue
Zheng" or "Gao Dan Gu Chun Xue Zheng" or "Gao
Gan You San Zhi Xue Zheng") and ("Yin Chen Wu
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Ling Sa"). However, the specific search procedure var-
ied in some cases given the different interface settings
of each database.
The bibliographies of included studies were also
searched for additional references. Academic annual
conference proceedings (from 2010 to 2015) of three
chapters of China Association of Chinese Medicine,
namely the Internal Medicine Chapter, Heart Disease
Chapter, and Zhongjing Doctrine Chapter, were
searched manually to identify additional studies. We
searched the seven databases for target articles with no
research type limitations. Gray literature or ongoing
studies were not included.
Data extraction and quality assessment
Two reviewers (HY and JZ) independently identified
the articles according to the established inclusion crite-
ria and extracted data for collection. The extracted data
included the authors and title of the study, year of pub-
lication, sample size, and age and sex of the partici-
pants, as well as details of methodological information
and control interventions. Chinese herbs, treatment
process, outcomes, and adverse effects were also includ-
ed. Disagreements were resolved by discussion and con-
sensus as mediated by a third reviewer (ZZ). The meth-
odological quality of the trials was assessed using seven
criteria from the Cochrane Handbook for Systematic
Review of Interventions, Version 5.10 (HY).18 The
items included random sequence generation (selection
bias), allocation concealment (selection bias), blinding
of participants and personnel (performance bias), blind-
ing of outcome assessment (detection bias), incomplete
outcome data (attrition bias), selective reporting (re-
porting bias), and other types of bias. Three levels were
used to evaluate the trials: low risk of bias (all the items
were in low risk of bias), high risk of bias (at least one
item was in high risk of bias), and unclear risk of bias
(at least one item was in unclear).
Data analysis
RevMan 5.3 software (ver. 5.3 RevMan, Copenhagen,
Denmark)19 provided by Cochrane Collaboration was
used for data analyses. The odds ratio (OR) of data was
calculated if the variables were dichotomous data, and
the weighted mean difference (WMD) was calculated
if the variables were continuous data, respectively, with
95% confidence intervals (CI). Heterogeneity between
trials was identified by the Chi-squares (χ2) test. When
there was acceptable homogeneity (P > 0.1, I 2 ≤ 50%),
the fixed effect model was used for Meta-analysis.
When heterogeneity was significant (P ≤ 0.1, I 2 >
50%), the random effect model was used.18
RESULTS
Description of studies
Sixty-eight relevant articles were identified and
screened, and only 32 remained after duplicate records
were deleted. After screening the titles and abstracts,
19 articles were excluded. Fifteen were excluded be-
cause they were not clinical trials, three were excluded
because their study focus was not only hyperlipidemia,
and one was excluded because it did not involve YC-
WLP. After reviewing the full texts, three were exclud-
ed because they lacked detailed data and only reported
differences between the treatment and control groups
after intervention. Another three were excluded be-
cause they were case reports or lacked a comparison
group. One study was excluded because hyperlipidemia
was only a complication and lipids were not the main
evaluating indexes. Another study was excluded be-
cause YCWLP was combined with simvastatin and was
not used alone in the trial. Therefore, five studies were
included in the final analysis.20-24 The flow diagram of
the abovementioned process is shown in Figure 1.
All five RCTs were conducted in China and published
in Chinese between 2001 and 2012. The characteris-
tics of those randomized trials are summarized in Table
1. A total of 363 patients were involved in the five tri-
als, and two different diagnosis criteria were followed.
One trial20 used the "Chinese Adult Dyslipidemia Pre-
vention Guide" (2007 edition), whereas another trial23
used the criteria made by the Geriatrics Research col-
laborative group in the National Administration of Tra-
ditional Chinese Medicine. The remaining three tri-
als21,22,24 only described patients with hyperlipidemia
and did not mention definite diagnostic criteria. All in-
cluded trials used YCWLP alone as the treatment mea-
sure. Among the five trials, one trial20 used simvastatin
as the control intervention, one trial21 used atorvas-
tatin, one trial23 used gypenoside, and the two remain-
ing trials22,24 used hexanicotol. The treatment duration
of the five trials was inconsistent. Four trials20,21,23,24 last-
ed for 4 weeks, and one22 lasted for 12 weeks. Other de-
tails are presented in Table 1.
Risk of bias in included studies
After evaluation, all studies included have a high risk
of bias and were considered of poor methodological
quality. All trials claimed that participants were ran-
domly allocated, but only one study20 stated the specif-
ic method of sequence generation as random number
table. The other four trials reported no detailed infor-
mation. Therefore, we could not evaluate the appropri-
ateness of their methods. The allocation concealment,
as well as the blinding of participants and personnel,
was not mentioned in all trials. None of the trials pro-
vided information about dropouts or withdrawals. All
of the included studies appeared to have adequate and
acceptable compliance. Selective reporting was general-
ly unclear because of the inaccessibility to the study
protocol. Other bias may exist but could not be con-
firmed given the lack of sufficient evidence. No con-
tact information was provided in the five articles.
Therefore, we were unable to obtain more details from
the authors (Figures 2 and 3).
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Effective rate
All five trials used YCWLP as the treatment group ver-
sus anti-lipemic agents as the control group. Three tri-
als21,23,24 used effective rate as an evaluation index, but
the criteria they used to define effective were not entire-
ly consistent. In the study by Zhang,21 effective was de-
fined as "TC reduced by ≥ 10% , TG reduced by ≥
20% , or HDL increased by ≥ 0.10 mmol/L." In the
study by Wang et al.,23 the effective criteria was "TC re-
duced by ≥ 10%, TG reduced by ≥ 20%, or HDL in-
creased by ≥ 4 mg/dL," whereas the criteria was "TC re-
duced by ≥ 10% or TG reduced by ≥ 20% " in the
study by Kang.24 The three independent trials showed
homogeneity in the results (P = 0.80, I 2 = 0%). There-
fore, we used a fixed-effects model to analyze the data
and confirmed that YCWLP had a significantly im-
proved clinical effective rate as compared with the con-
trol group (OR=3.57; 95%CI = [1.49, 8.51]) (Figure 4).
TC
All five studies compared the effect of lowering TC be-
tween the treatment and control groups, but they
showed heterogeneity (P < 0.00001, I 2 = 96%). After
conducting the sensitivity analysis, we excluded the
study by Hu (2012). The data then showed acceptable
homogeneity (P = 0.18, I 2 = 39%), so the fixed-effects
model was used to pool the data. A forest plot demon-
strated that the treatment group was significantly more
effective than the control group［(MD = −0.50; 95%
CI = (−0.53, −0.47)] (Figure 5).
TG
All five studies used TG as an outcome measurement,
but they showed significant heterogeneity (P = 0.02;
I 2 = 66%). The study by Wang et al.23 (P = 0.55; I 2 =
0% ) was excluded, and the fixed-effects model was
used to conduct the statistical analysis. YCWLP had a
68 records identified
through database
searching
0 additional records
identified through
other sources
32 records after duplicates removed
32 records screened
19 records excluded:
Animal study, literature review or
theoretical research (n = 15)
Not about YCWLP (n = 1)
Not about hyperlipidemia (n = 3)
13 full-text articles
assessed for eligibility
8 full-text articles excluded, with reasons:
Lack of detailed data (n = 3)
Case reports or case series (n = 3)
Lipid is not the main evaluating index (n = 1)
The intervention was not YCWLP alone (n = 1)
5 studies included in
qualitative synthesis
5 studies included
in quantitative
synthesis
(Meta-analysis)
Figure 1 Study flow diagram
YCWLP: Yinchenwuling power
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better effect on lowering the TG than that of the lip-
id-lowering drugs [MD = －0.12; 95% CI = (－0.14,
－0.10)] (Figure 6).
HDL
Four studies20-23 reported a comparison of HDL be-
tween the treatment group and the control group after
intervention. The data of the four trials showed homo-
geneity (P = 0.85, I 2 = 0%). Therefore, the fixed-effect
model was used. Meta-analysis demonstrated that YC-
WLP was more effective than lipid-lowering drugs in
increasing HDL [MD = 0.07; 95% CI = (0.03, 0.11)]
(Figure 7).
LDL
Only two studies20,23 compared the effect of lowering
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Low risk of bias Unclear risk of bias High risk of bias
0% 25% 50% 75% 100%
Figure 2 Risk of bias graph
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Hu2012
Kang2000
Liu2004
Wang2001
Zhang2011
Figure 3 Risk of bias summary
Figure 4 Effective rate of Yinchenwuling power versus lipid-lowering drugs
Figure 5 Total chole sterol of Yinchenwuling power versus lipid-lowering drugs
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LDL between treatment and experimental group after
intervention. The data showed significant heterogene-
ity (P = 0.009, I 2 = 85%), therefore, the random ef-
fects model was chosen to analyze the data. Results
showed that YCWLP was not more effective than lip-
id-lowering drugs in reducing LDL (MD = − 0.46;
95% CI = [−1.21, 0.29]) (Figure 8).
Hemodynamic indexes
Two trials20,23 explored the effect on hemorheology by
testing the changes of some indexes after intervention
between the treatment and control groups. Both stud-
ies used three hemorheology indexes, namely, the high
shear rate blood viscosity, low shear rate blood viscosi-
ty, and the plasma viscosity. The three data groups of
two trials all showed heterogeneity. After analyzing the
data with the random effects model, we found that YC-
WLP was not more effective than the lipid-lowering
drugs in improving hemorheology (Figures 9-11).
Figure 6 Total triglyceride of Yinchenwuling power versus lipid-lowering drugs
Figure 7 High-density lipoprotein cholesterol of Yinchenwuling power versus lipid-lowering drugs
Figure 8 Low-density lipoprotein of Yinchenwuling power versus lipid-lowering drugs
Figure 9 High shear rate blood viscosity of Yinchenwuling power versus lipid-lowering drugs
Figure 10 Low shear rate blood viscosity of Yinchenwuling power versus lipid-lowering drugs
Figure 11 Plasma viscosity of Yinchenwuling power versus lipid-lowering drugs
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Adverse events
Adverse events were reported in three trials,20,21,24 which
involved 4 patients in the treatment group and 37 pa-
tients in the control group. Three kinds of side effects
were observed. In the control group, 16 patients suf-
fered from abnormally elevated alanine aminotransfer-
ase levels and 4 patients had flushed skin or itching.
Meanwhile, 4 patients in the treatment group and 17
patients in the control group were reported to have ab-
dominal pain, bloating, or constipation. The data
showed homogeneity (P = 0.71, I 2 = 0%), so the fixed
effect model was chosen for Meta-analysis. YCWLP
had a lower odds ratio of adverse events than the lip-
id-lowering drugs [OR = − 0.08, 95% CI = (0.03,
0.23)] (Figure 12).
DISCUSSION
Summary of the main findings
Five RCTs involving 363 patients were included in the
Meta-analysis. The data and forest plots demonstrated
that YCWLP might be more effective at lowering lipid
levels than conventional drugs used to treat hyperlipid-
emia. Based on the Meta-analysis, our preliminary con-
clusion was that YCWLP had a significantly improved
clinical effective rate as compared with the control
group. YCWLP was more effective in lowering TC and
TG and increasing HDL. However, YCWLP was not
more effective than the lipid-lowering drugs in reduc-
ing LDL and improving hemorheology. Three trials re-
ported side effects but showed that YCWLP has fewer
adverse events and may be potentially safer than lip-
id-lowering drugs.
Strengths and limitations
This is the first systematic review and Meta-analysis
that evaluates the efficacy and safety of YCWLP in
treating hyperlipidemia. This study was conducted ac-
cording to the PRISMA statement and followed a stan-
dard protocol that was registered in PROSPERO (regis-
tration number: CRD42015019428), an international
prospective register of systematic reviews. All reviewers
in this study have an academic qualification in Tradi-
tional Chinese Medicine. The literature search compre-
hensively and rigorously assessed the methodological
quality of the included trials.
This Meta-analysis has several limitations. The includ-
ed trials were of poor methodological quality. Only
one study reported a randomization procedure, where-
as the other four trials merely stated that the patients
were randomly divided into two groups. Given the lack
of necessary information in the articles, we could not
judge whether randomization was properly conducted.
All five studies lacked information on allocation con-
cealment, as well as the blinding of participants, per-
sonnel, and the outcome assessment. None of the stud-
ies reported dropouts or loss to follow-up, and the in-
tention-to-treat analysis and pre-trial sample size esti-
mates were not mentioned. In addition, reporting on
adverse events was inadequate. The information about
quality control and qualitative testing for the herbal
preparations was lacking, which is a common problem
in Chinese clinical trials. Given the insufficient num-
ber of included trials in this Meta-analysis, we could
not perform a funnel plot analysis. Therefore, potential
publication bias may be present.
In conclusion, the results of the included trials and Me-
ta-analysis suggest that YCWLP may be more effective
than lipid-lowering drugs in treating hyperlipidemia.
However, the evidence available from this study is in-
sufficient to draw a conclusion that confirms the bene-
ficial effects of YCWLP on hyperlipidemia. Positive
findings should be conservatively interpreted because
of the methodological limitations of the included trials.
Additional well-designed clinical trials need to be con-
ducted to verify the effectiveness and safety of YCWLP
for hyperlipidemia. Through the present Meta-analysis,
we obtained some implications for future clinical stud-
ies. Sample size estimation should be conducted before
enrollment. Adequate information on methodology
should also be provided, such as randomization, alloca-
tion concealment, and blinding methods. The inten-
tion to treat analysis and dropouts during the trial
should be clearly described. Follow-up should be taken
to assess the long-term effectiveness and safety of the
intervention. More attention should be paid to the ad-
verse events reporting. Furthermore, clinical trials
should be registered in the WHO International Clini-
cal Registry Platform in advance and should follow the
CONSORT statement25 or CONSORT extension for
Herbal Interventions.26 with detailed information ad-
dressed.
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